Lyell Immunopharma. has been granted a patent for EGFR-derived polypeptides that enhance the cell surface expression of truncated EGFR markers. The patent includes nucleic acids encoding these polypeptides, which feature specific extracellular and intracellular regions, excluding certain EGFR domains. GlobalData’s report on Lyell Immunopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lyell Immunopharma, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Lyell Immunopharma's grant share as of July 2024 was 2%. Grant share is based on the ratio of number of grants to total number of patents.
Egfr-derived polypeptides for improved cell surface expression
The patent US12054531B2 describes a novel nucleic acid molecule that encodes a recombinant polypeptide featuring distinct structural regions: an extracellular region, a transmembrane region, and an intracellular region. The extracellular region specifically includes a human epidermal growth factor receptor (EGFR) Domain III sequence, while intentionally excluding EGFR Domains I and II. The intracellular region is characterized by a juxtamembrane domain that is net-neutral or net-positively charged in its initial amino acids and notably lacks an EGFR tyrosine kinase domain. The claims also encompass cells, particularly human T cells, that contain this nucleic acid molecule, as well as pharmaceutical compositions that incorporate the nucleic acid or recombinant virions.
Additionally, the patent outlines methods for creating genetically engineered human cells by introducing the nucleic acid molecule into isolated human cells. The claims further specify various configurations of the juxtamembrane domain, including specific amino acid sequences and the potential inclusion of a chimeric antigen receptor (CAR) that targets tumor antigens. The nucleic acid molecule can also be linked to additional coding sequences, allowing for co-transcription under the same promoter, which may be either constitutive or inducible. The patent highlights the versatility of the nucleic acid molecule, which can be delivered via viral vectors, such as lentiviral vectors, thereby expanding its potential applications in therapeutic contexts, particularly in cancer treatment and immunotherapy.
To know more about GlobalData’s detailed insights on Lyell Immunopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
